Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) Director Sells $828,950.26 in Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Director Louis Lange sold 28,186 shares of NewAmsterdam Pharma stock in a transaction dated Friday, March 6th. The stock was sold at an average price of $29.41, for a total value of $828,950.26. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

NewAmsterdam Pharma Stock Performance

NASDAQ NAMS opened at $29.82 on Friday. NewAmsterdam Pharma Company N.V. has a fifty-two week low of $14.06 and a fifty-two week high of $42.00. The company has a market cap of $3.43 billion, a P/E ratio of -17.24 and a beta of 0.04. The business’s 50 day moving average price is $33.24 and its 200-day moving average price is $33.32.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its earnings results on Wednesday, February 18th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($0.23). NewAmsterdam Pharma had a negative net margin of 906.22% and a negative return on equity of 26.67%. The firm had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.92 million. As a group, equities analysts predict that NewAmsterdam Pharma Company N.V. will post -1.75 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on NAMS. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Thursday, January 22nd. Needham & Company LLC raised their price target on shares of NewAmsterdam Pharma from $46.00 to $48.00 and gave the company a “buy” rating in a report on Wednesday, February 18th. Cantor Fitzgerald reiterated an “overweight” rating on shares of NewAmsterdam Pharma in a research note on Thursday, February 19th. Stifel Nicolaus increased their target price on shares of NewAmsterdam Pharma from $44.00 to $50.00 and gave the company a “buy” rating in a research report on Tuesday, December 16th. Finally, The Goldman Sachs Group raised their target price on shares of NewAmsterdam Pharma from $30.00 to $37.00 and gave the company a “neutral” rating in a research note on Tuesday, December 2nd. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $47.10.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Seven Fleet Capital Management LP acquired a new stake in shares of NewAmsterdam Pharma during the fourth quarter worth about $140,000. Empowered Funds LLC purchased a new position in NewAmsterdam Pharma during the 4th quarter worth approximately $85,000. XTX Topco Ltd lifted its stake in NewAmsterdam Pharma by 1,714.1% during the 4th quarter. XTX Topco Ltd now owns 137,492 shares of the company’s stock valued at $4,823,000 after acquiring an additional 129,913 shares during the period. Virtus Investment Advisers LLC lifted its stake in NewAmsterdam Pharma by 32.0% during the 4th quarter. Virtus Investment Advisers LLC now owns 7,142 shares of the company’s stock valued at $251,000 after acquiring an additional 1,731 shares during the period. Finally, Twinbeech Capital LP purchased a new stake in shares of NewAmsterdam Pharma in the 4th quarter valued at $961,000. 89.89% of the stock is currently owned by hedge funds and other institutional investors.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.